EP2459721A1 - Improved human long pentraxin 3 expression system and uses thereof - Google Patents

Improved human long pentraxin 3 expression system and uses thereof

Info

Publication number
EP2459721A1
EP2459721A1 EP10740573A EP10740573A EP2459721A1 EP 2459721 A1 EP2459721 A1 EP 2459721A1 EP 10740573 A EP10740573 A EP 10740573A EP 10740573 A EP10740573 A EP 10740573A EP 2459721 A1 EP2459721 A1 EP 2459721A1
Authority
EP
European Patent Office
Prior art keywords
recombinant
long pentraxin
cell
human
human long
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP10740573A
Other languages
German (de)
French (fr)
Other versions
EP2459721B1 (en
Inventor
Marica Sassano
Adelaide Esposito
Vincenzo Rivieccio
Giovanni Cassani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Tecnogen SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tecnogen SpA filed Critical Tecnogen SpA
Priority to EP10740573.0A priority Critical patent/EP2459721B1/en
Priority to PL10740573T priority patent/PL2459721T3/en
Priority to MEP-2013-126A priority patent/ME01566B/en
Priority to SI201030362T priority patent/SI2459721T1/en
Publication of EP2459721A1 publication Critical patent/EP2459721A1/en
Application granted granted Critical
Publication of EP2459721B1 publication Critical patent/EP2459721B1/en
Priority to CY20131100942T priority patent/CY1116486T1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal

Definitions

  • the present invention relates to human derived cellular system able to express high levels of the human pentraxin 3 (hPTX3) protein, methods and material used.
  • hPTX3 human pentraxin 3
  • Human long pentraxin 3 is a multimeric glycoprotein composed of eight subunits linked by disulphide bridges.
  • the authors of the present invention have already designed an expression system for the production of PTX3 in HEK293F human cell line.
  • This system is based on a plasmid containing the neomycin resistance gene wherein the PTX3 gene is under the control of a human Ubiquitin C promoter sequence.
  • Such system avoids the potential formation of a chimeric PTX3 derived from endogenous production of PTX3 by a cell line of non-human origin.
  • the best producer isolated clone, named 2Fl 2 was selected among those obtained. A production of about 20 mg/L of PTX3 was obtained, which was not sufficient for commercial production needs.
  • the authors of the present invention have constructed a plasmid in which the PTX3 gene was under CMV promoter control.
  • the plasmid was used to re-trans feet the PTX3 expressing clone 2Fl 2.
  • the productivity level detected in the new isolated transfectomas was higher that expected, around 80 mg/L.
  • a clone of human origin expressing high levels of human PTX3 was obtained using an experimental strategy , including the following steps:
  • the vector is preferentially use to transform host cell, preferably wherein the host cell is a recombinant human cell already able to express the human long pentraxin PTX3 protein, more preferably wherein the recombinant human cell is the recombinant 293F/PTX3/2F12 clone deposited at ECACC with no. 08011001.
  • the vector is linearized.
  • It is another object of the invention a process for the production of the recombinant human long pentraxin PTX3 protein comprising:
  • the recombinant human cell expressing a recombinant human long pentraxin PTX3 protein is a recombinant HEK293F cell line, more preferably it is the recombinant
  • the purification step includes at least one of the following step: anionic-exchange chromatography, hydroxyapatite chromatography or size exclusion chromatography.
  • It is another object of the invention a process for the production of the recombinant human long pentraxin PTX3 protein comprising:
  • It is another object of the invention a process for the production the recombinant human long pentraxin PTX3 protein comprising the step of growing the recombinant MS24PTX clone and purifying the human long pentraxin PTX3 protein from the culture medium.
  • Figure 1 pSASSI-hPTX3 map and main features
  • Figure 2 Growth, viability and productivity in Spinner Flask of (A) MS24PTX clone and (B)
  • FIG. 4 FGF2 binding capability of hPTX3 clone 293F/PTX3/2F12 and hPTX3 clone
  • Figure 5 pSCl-hPTX3 map and main features.
  • the human ubiquitin C promoter is taken from pUB/Bsd plasmid (Invtrogen, Cat. n. V512-20), by amplification with PCR. As part of the cloning strategy, recognition sequences for restriction endonucleases are introduced at both ends. A BsaAI site is built in the upstream amplification primer and an EcoRI site in the downstream primer. The amplified region corresponds to nucleotides 1941 to 3161 in the sequence of pUB/Bsd.
  • oligonucleotides are designed as follow:
  • the protocol for amplification is the following: 1 ng/ ⁇ l of plasmid DNA, 2mM MgC12, 0,2 mM dNTPs, 40OnM of each primer, IX supplied buffer and 0,04 u/ml of Taq DNA polymerase (Sigma Genosys); temperature profile: 3 min 94°C, 30 times (30 sec. 94°C, 30 sec. 46°C, 2 min 72°C), 5 min 72°C, cooling at 4°C until further use.
  • the amplification product (1238 bp) is purified by silica membrane spin column ( NucleoSpin, Machery-Nagel GmbH & Co.), ligated in pGEM-T-Easy vector (Promega Cat. n. A1360) and transformed into E.coli host strain HB2151 (Pharmacia Biotech). Transformants are selected by growth on LB medium supplemented with 50 mg/1 ampicillin
  • Plasmids DNA isolated from ampicillin resistant colonies, are checked by restriction analysis with Stul plus Sad enzymes (expected ⁇ 3650 and 600 bp fragments)
  • Plasmids showing the correct restriction pattern are further checked by sequence analysis of the entire insert and subsequently digested with EcoRI (Sigma-Genosys) and BsaAI (New England Biolabs) restriction enzymes.
  • Human Ubiquitin C promoter is purified via agarose gel separation and elution on silica membrane spin column.
  • Plasmid pSG5 (4076 bp, Stratagene) was cut with the restriction enzymes EcoRI (Sigma- Genosys) and BsaAI (New England Biolabs); the resulting fragments are 1432 and 2644 bp long.
  • DNA fragments prepared in steps 1.1 and 1.2 were ligated using T4 DNA ligase (Promega) and transformed in HB2151 E. coli cells. Transformants were selected by growth on LB medium supplemented with 50 mg/1 ampicillin.
  • Plasmid DNA isolated from ampicillin resistant colonies, was checked by restriction analysis with EcoRI plus SacII enzymes (expected: 2670 and 1192 bp fragments). A plasmid DNA, with the expected restriction pattern, was designed as pSG/Ub.
  • Neomycin Resistance Cassette (NeoR)
  • Neomycin Resistance Cassette (NeoR) was taken from pcDNA3 plasmid (5446 bp, Invitrogen), amplifying it by PCR. As part of the cloning strategy, recognition sequences for restriction endonuclease AflIII were introduced at both ends. The amplified region corresponds to nucleotides 1788 to 3252 in the sequence of pcDNA3 and includes the SV40 promoter and origin of replication, the neomycin resistance ORF, and the SV40 poliA signal.
  • oligonucleotides are designed as follows: 5'NeoR (SEQ ID 5) ATATACATG TCC CCA GGC AGG CAG AA
  • Protocol for amplification was the following: 1 ng/ ⁇ l of plasmid DNA, 2mM MgC12, 0,2 mM dNTPs, 40OnM of each primer, IX supplied buffer and 0,04 u/ ⁇ l of Taq DNA polymerase (Sigma Genosys); temperature profile: 3 min 94°C, 30 times (30 sec. 94°C, 30 sec. 46°C, 2 min
  • the amplification product (1484 bp) was purified by silica membrane spin column, ligated in pGEM-T-Easy vector (Promega Cat. n. A1360) and transformed into E.coli host strain HB2151.
  • Trans formants are selected by growth on LB medium, supplemented with 50 mg/1 ampicillin Plasmids DNA, isolated from ampicillin resistant colonies, are checked by restriction analysis with Smal plus Sad enzymes (expected ⁇ 1200 and 3300 bp fragments).
  • Plasmids showing the correct restriction pattern were further checked by sequence analysis of the entire insert and subsequently digested with AfIIII (New England Biolabs) restriction enzymes.
  • NeoR cassette (1471 bp) was purified via agarose gel separation and elution on silica membrane spin column.
  • DNA fragments prepared as in steps 2.1 and 2.2 were ligated using T4 DNA ligase (Promega) and transformed in JMl 09 E. coli strain (New England Biolabs). Transformants were selected by growth on LB medium, supplemented with 50 mg/1 ampicillin.
  • Antibiotic resistant colonies were preliminarliy analyzed by PCR amplification with 5 'NeoR and 3 'NeoR oligonucleotides, as previously described, and subsequently, purified plasmids were checked by restriction analysis.
  • Smal position 602, inside NeoR sequence
  • SacII position 4142, inside UbC sequence
  • a plasmid DNA, with the expected restriction pattern (3540 and 1793 bp fragments) was designed as pSCl.
  • hPTX3 GeneBank Accession Number BD 131701
  • sequence was taken from pSG5-PTX3 (WO 99/32516 "Pharmaceutical compositions containing the long pentraxin PTX3 ) by BamHI (Roche Applied Science) digestion.
  • Human PTX3 fragment 1463 bp was purified by agarose gel electrophoresis and silica membrane spin column.
  • the pSCl vector was linearized by BamHI digestion and purified on silica membrane spin column.
  • DNA fragments prepared in steps 3.2 and 3.3 were ligated using T4 DNA ligase (Roche Applied Science) and transformed in JM 109 E. coli strain. Transformants were selected by growth on LB medium, supplemented with 50 mg/1 ampicillin and preliminarily screened by PCR with two oligonucleotides complementary to PTX3 sequence.
  • the oligonucleotides sequences are:
  • reagents for amplification were: 1 ⁇ l of boiled colony (1 colony in 50ml of water), 2mM MgC12, 0,2 mM dNTPs, 32OnM of each primer, 0,06% Formamide, IX supplied buffer and 0,08 u/ ⁇ l of Taq DNA polymerase (Sigma Genosys); temperature profile: 3 min 96°C, 30 times (30 sec. 94°C, 30 sec. 58°C, 2 min 72°C), 5 min 72°C, cooling at 4°C until further use.
  • Plasmid purified from colonies positive to PCR screening were digested with Sail restriction enzyme (Roche Applied Science) to check the orientation of hPTX3 insert.
  • a plasmid with the expected restriction pattern (6619 and 177 bp) was sequenced in the regions coding for UbC promoter, NeoR cassette and hPTX3 and identified as pSCl-PTX3.
  • the new plasmid (pSCl-PTX3) was then constructed with PTX3 cDNA sequence located under ubiquitin promoter control and neomycin resistance gene under SV40 promoter control; all other features and plasmid map are represented in figure 1.
  • the complete sequence of pSCl-PTX3 is as follows (SEQ ID 2).
  • the pSCl-hPTX3 sequence is represented starting from the first EcoRI site (figure 5).
  • the sequence deriving from pSG5 containing PTX3 cDNA is underlined.
  • the starting codon (ATG) and termination codon are in bold.
  • TTTTTTGTTAGACCGGACCG A human cell line (HEK293F) has been chosen for its ability to grow in suspension and in a serum and protein free medium (Florian M Wurm “Production of recombinant protein therapeutics in cultivated mammalian cells” Nature Biotechnology 22(11): 1393-1398, 2004, Yan SC et al. "Characterization and novel purification of recombinant human protein C from three mammalian cell lines” Biotechnology (N.Y.) 1990 JuI 8 (7): 655-61. "Use of cell lines for the production of influenza virus vaccines: an appraisal of technical, manufacturing, and regulatory considerations” Initiative for Vaccine Research, World Health Organization, Geneva, Switzerland (10 Aprile 2007).
  • pSCl-PTX3 plasmid was used either in a linear (Pvul digested) or in a circular form. The best transfection yield was obtained with linearized plasmid; clones selection was done on a productivity base and growth capability. After several rounds of subcloning the 2Fl 2 clone was selected.
  • the human clone 2Fl 2, expressing hPTX3, has been deposited at ECACC (European Collection of Cell Cultures, Health Protection Agency, Porton Down, Wiltshire SP4 OJG, UK) on January 10, 2008, pursuant to Budapest Treaty condition under deposit number 0801 1001. The experimental details are described below.
  • the medium was changed into selection medium (200 ml Freestyle medium+ 500 ⁇ g/ml of G418) and the transfected cells were plated in ten 96wells plates, 200 ⁇ l/well. After 15 days highest producers cell-pools were determined by ELISA and amplified in 24wells, ⁇ wells and T25flask.
  • Recombinant cell-pools obtained were subcloned with 1 cells per well in 96wells plates, in 50% fresh medium and 50% conditioned medium.
  • pCEP4 plasmid (Invitrogen cat. n. V044-50), in which was previously cloned an antibody light chain, loosing a portion of the Multiple Cloning Site and the BamHI restriction site, was cut with the restriction enzymes EcoRV and CIaI (Roche Applied Science); the digestion allowed to obtain a plasmid without the Epstein-Barr- Virus replication origin (oriP) and the nuclear antigen (encoded by the EBNA-I gene) that permit extrachromosomal replication. The resulting fragments were 6910 and 4281 bp long.
  • the fragment was purified on a silica membrane spin column and ligated on itself over night at room temperature, by using T4 DNA ligase (Promega).
  • TOPlO competent cells (Invitrogen) were transformed with the ligation mixture and transformants selected by growth on LB plates supplemented with 100 mg/L ampicillin.
  • Plasmid DNA isolated from ampicillin resistant colonies, was designed as pCEPlight ⁇ .
  • the Hygromycin Resistance Cassette together with the cytomegalovirus (CMV) immediate early enhancer/promoter was taken from pCEPlight ⁇ amplifying it by PCR.
  • recognition sequence for restriction endonuclease BamHI was introduced in the oligonucleotide annealing to the 3' end of CMV promoter.
  • the amplified region about 5500 bp included CMV promoter, Hygromycin gene under the control of TK promoter together with TK polyA signal.
  • the oligonucleotide are designed as follows:
  • oligo CMV (SEQ ID 9) 5 'GAGAACTGTAACGTTGGATCCAGCTGG S '
  • Protocol for amplification was the following: 2 ng of pCEPlight ⁇ , 20OnM of each primer, 0,2 mM dNTPs, IX supplied buffer, 1.5 ⁇ l DMSO, 0.5 ⁇ l Taq DNA polymerase (Phusion), final volume 50 ⁇ l; temperature profile: 1 min 98°C, 35 times (10 sec. 98°C, 30 sec. 55°C, 3 min. 72°C), 10 min. 72°C, cooling at 4°C until further use.
  • the amplification product (-5500 bp) was purified via agarose gel electrophoresis plus silica membrane spin column. Purified fragment was ligated to itself and use to transform TOPlO competent cells (Invitrogen). Plasmid DNA, isolated from ampicillin resistant colonies, was checked by restriction and sequence analysis, and was designed as pCEP ⁇ Bam.
  • hPTX3 GeneBank Accession Number BD 131701
  • sequence was taken from pSCl-PTX3 as indicated above by BamHI (Roche Applied Science) digestion.
  • Human PTX3 fragment (1463 bp) was purified by agarose gel electrophoresis and silica membrane spin column.
  • the pCEP ⁇ Bam vector was linearized by BamHI digestion and purified on silica membrane spin column.
  • pCEP ⁇ Bam linearized and DNA fragment corresponding to hPTX3 gene prepared in step 3 were ligated using T4 DNA ligase (Roche Applied Science) and used to transform TOPlO E. coli strain.
  • Transformants were selected by growth on LB medium, supplemented with 100 mg/L ampicillin and preliminarily screened restriction analisys to evaluate PTX3 fragment orientation.
  • the SV40 polyA signal was taken from pCEP ⁇ light plasmid amplifying it by PCR.
  • recognition sequences for restriction endonucleoases HindIII and Xhol were introduced at fragment ends respectively.
  • oligonucleotides were designed as follows:
  • PCEPSVH (SEQ ID 11) 5 'AAGCTT AGAC ATGAT AAGAT AC ATTG 3'
  • PCEPSVX (SEQ ID 12) 5'CTCGAGAGTCGACCGGTCATGGCTGC 3' Protocol for amplification was the following: 1 ng of pCEPlight ⁇ , 20OnM of each primer, 0,2 mM dNTPs, IX supplied buffer, 2 ⁇ l MgC12 5OmM, 0.5 ⁇ l Taq DNA polymerase (Invitrogen), final volume 50 ⁇ l; temperature profile: 1 min 94°C, 30 times (30 sec. 94°C, 1 min. 55°C, 1 min. 72°C), 15 min. 72°C, cooling at 4°C until further use.
  • the amplification product (-420 bp) was purified via agarose gel electrophoresis plus silica membrane spin column.
  • Purified fragment corresponding to SV40 polyA signal and pCEP ⁇ Bam-hPTX3 were digested with Hindlll/Xhol restriction enzymes and ligated using T4 DNA ligase (Promega). Ligation mixture was used to transform TOPlO competent cells (Invitrogen) and transformants were selected by growth on LB plates containing 100 mg/L of ampicillin.
  • the complete sequence of pSASSI-HPTX3 is as follow (SEQ ID 1).
  • the pSASSI-hPTX3 sequence is represented starting from the BamHI site (figure 1).
  • the sequence of hPTX3 is in small letters.
  • the starting codon (atg) and the termination codon (taa) are in bold.
  • TAGTAGTATA TACTATCCAG ACTAACCCTA ATTCAATAGC ATATGTTACC CAACGGGAAG 2340 CATATGCTAT CGAATTAGGG TTAGTAAAAG GGTCCTAAGG AACAGCGATC GATGATAAGC 2400
  • GTAACTGTCA GACCAAGTTT ACTCATATAT ACTTTAGATT GATTTAAAAC TTCATTTTTA 3540 ATTTAAAAGG ATCTAGGTGA AGATCCTTTT TGATAATCTC ATGACCAAAA TCCCTTAACG 3600
  • CTCTGTAGCA CCGCCTACAT ACCTCGCTCT GCTAATCCTG TTACCAGTGG CTGCTGCCAG 3900 TGGCGATAAG TCGTGTCTTA CCGGGTTGGA CTCAAGACGA TAGTTACCGG ATAAGGCGCA 3960
  • GCGAACGCCA GCAAGACGTA GCCCAGCGCG TCGGCCGCCA TGCCCTGCTT CATCCCCGTG 4800 GCCCGTTGCT CGCGTTTGCT GGCGGTGTCC CCGGAAGAAA TATATTTGCA TGTCTTTAGT 4860
  • CAGTCGGGGC GGCGCGGTCC CAGGTCCACT TCGCATATTA AGGTGACGCG TGTGGCCTCG 4980
  • CTCTCGATGA GCTGATGCTT TGGGCCGAGG ACTGCCCCGA AGTCCGGCAC CTCGTGCACG 5640
  • TATTAGTCAT CGCTATTACC ATGGTGATGC GGTTTTGGCA GTACACCAAT GGGCGTGGAT 7260
  • the medium was changed into selection medium (200 ml Freestyle medium+ 200 ⁇ g/ml of Hygromycin) and the transfected cells were plated in ten 96wells plates, 200 ⁇ l/well. After 15 days highest producers cell-pools were determined by ELISA and amplified in 24wells, ⁇ wells and T25 flask.
  • Recombinant cell-pools obtained were subcloned with 1 cells per well in 96wells plates, in 50% fresh medium and 50% conditioned medium.
  • Purified PTX3 or PTX3 secreted in the culture supernatant were titrated using a sandwich ELISA.
  • 96-well Nunc Maxisorb microtiter plates (Nunc, Roskilde, Denmark) were coated overnight, at 4°C, with 700 ng/ml of the rat monoclonal antibody MNB4 anti-human PTX3 (AlexisTM Biochemicals, Lausen, Switzerland) in 15mM sodium carbonate buffer, pH 9.6.
  • Wells were washed with PBS plus 0.05% Tween-20 (PBS-Tw, washing solution) and blocked with 300 ⁇ l of PBS-Tw containing 5% dry milk, for 2 hours at room temperature.
  • Figure 2 shows the growth, viability and productivity of the MS24PTX (panel A) and 293F/PTX3/2F12 (panel B) clones in the same seeding and growing conditions.
  • PTX3 expressing clone 293F/PTX3/2F12
  • CMV promoter a new plasmid in which PTX3 is under the control of CMV promoter
  • the PTX3 -containing fraction was concentrated and buffer changed on a ultrafiltration membrane (Pellicon-Biomax 100, Millipore) than characterized by Size Exclusion Chromatography on Biosep SEC S4000 (Phenomenex) and SDS-PAGE ( Figure 3).
  • a ultrafiltration membrane Pellicon-Biomax 100, Millipore
  • Size Exclusion Chromatography on Biosep SEC S4000 Phenomenex
  • SDS-PAGE Figure 3
  • the binding of purified recombinant hPTX3 to FGF2 was assessed in an ELISA system.
  • a 96- wells plate (Falcon 3912) was coated with 2 ⁇ g/ml of FGF2 (Calbiochem) in PBS and incubated overnight at 4°C.
  • Wells were washed with PBS plus 0.1% Triton X-100 (PBS-Tr, washing solution) and blocked with 200 ⁇ l of PBS-Tr containing 3% BSA (PBS-B blocking and diluent solution) for 2 hours at room temperature.
  • PBS-Tr Triton X-100
  • binding was performed adding 100 ⁇ l of samples, diluted in PBS-B at PTX3 concentrations ranging from 0 to 120 ng/ml, and incubating the plate at 37°C for 1 hr. After wash, plates were incubated with 100 ⁇ l/well of 100 ng/ml rabbit anti-PTX3 polyclonal antibody (1 hr at 37°C), washed again and incubated with 100 ⁇ l of horseradish peroxidase-labeled goat anti-rabbit IgG (1 :1000 in PBS-B; 1 hr at 37°C).

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)

Abstract

The present invention relates to an eukaryotic expression vector comprising a nucleotide sequence encoding for the human long pentraxin PTX3 protein under the control of an effective promoter and a nucleotide sequence encoding for a selectable marker, recombinant human cell able to provide expression of proteins encoded by the vector and method for the production of the human long pentraxin PTX3 protein.

Description

IMPROVED HUMAN LONG PENTRAXIN 3 EXPRESSION SYSTEM AND USES
THEREOF
FIELD OF THE INVENTION
The present invention relates to human derived cellular system able to express high levels of the human pentraxin 3 (hPTX3) protein, methods and material used.
BACKGROUND TO THE INVENTION
Human long pentraxin 3, PTX3 or hPTX3 (GeneBank Accession Number BD 131701) is a multimeric glycoprotein composed of eight subunits linked by disulphide bridges.
The authors of the present invention have already designed an expression system for the production of PTX3 in HEK293F human cell line. This system is based on a plasmid containing the neomycin resistance gene wherein the PTX3 gene is under the control of a human Ubiquitin C promoter sequence. Such system avoids the potential formation of a chimeric PTX3 derived from endogenous production of PTX3 by a cell line of non-human origin. The best producer isolated clone, named 2Fl 2, was selected among those obtained. A production of about 20 mg/L of PTX3 was obtained, which was not sufficient for commercial production needs.
With the aim to increase PTX3 expression levels, the authors of the present invention have constructed a plasmid in which the PTX3 gene was under CMV promoter control. The plasmid was used to re-trans feet the PTX3 expressing clone 2Fl 2. The productivity level detected in the new isolated transfectomas was higher that expected, around 80 mg/L.
DESCRIPTION OF THE INVENTION
A clone of human origin expressing high levels of human PTX3 was obtained using an experimental strategy , including the following steps:
a) construction of plasmid expression cassettes carrying the human PTX3 under the control of CMV promoter;
b) insertion of the hygromycin resistance cassette in said plasmid, in order to select stable transfectomas originating from a re-transfection of PTX3 expressing clone G418 resistant;
c) verifying the identity and the levels of expressed recombinant proteins;
d) biochemical characterization of the recombinant hPTX3.
The content of PCT/EP2009/050937 is hereby incorporated by reference. It is an object of the invention an eukaryotic expression vector comprising a nucleotide sequence encoding for the human long pentraxin PTX3 protein under the control of an effective promoter and a nucleotide sequence encoding for a selectable marker, having essentially the sequence of SEQ ID 1.
The vector is preferentially use to transform host cell, preferably wherein the host cell is a recombinant human cell already able to express the human long pentraxin PTX3 protein, more preferably wherein the recombinant human cell is the recombinant 293F/PTX3/2F12 clone deposited at ECACC with no. 08011001. In a particular aspect the vector is linearized.
It is another object of the invention a recombinant cell able to express the human long pentraxin PTX3 protein encoded by the vector as above disclosed, preferably it is recombinant HEK293F cell line, more preferably it is the recombinant MS24PTX clone deposited at Health Protection Agency, Culture Collections Centre For Emergency Preparedness and Response Salisbury UK, with no. 09072902.
It is another aspect of the invention the use of the recombinant cell as above disclosed for the production of human long pentraxin PTX3 protein.
It is another object of the invention a process for the production of the recombinant human long pentraxin PTX3 protein comprising:
a) transfecting a recombinant human cell already expressing recombinant human long pentraxin PTX3 protein, with a selectable plasmid in which the human long pentraxin gene is under the control of the CMV promoter ;
b) selecting and growing transfected recombinant human cell;
c) purifying the human long pentraxin PTX3 protein from the culture medium of the transfected recombinant human cell.
Preferably the recombinant human cell expressing a recombinant human long pentraxin PTX3 protein is a recombinant HEK293F cell line, more preferably it is the recombinant
293F/PTX3/2F12 clone deposited at ECACC under number 08011001.
In a preferred embodiment the purification step includes at least one of the following step: anionic-exchange chromatography, hydroxyapatite chromatography or size exclusion chromatography.
It is another object of the invention a process for the production of the recombinant human long pentraxin PTX3 protein comprising:
a) co-transfecting contemporarily or sequentially human cells with a first vector having essentially the sequence of SEQ ID 1 and a second vector having essentially the sequence of
SEQ ID 2; b) selecting and growing the double transfected cells;
b) purifying the human long pentraxin PTX3 protein from the culture medium of double transfected cells.
It is another object of the invention a process for the production the recombinant human long pentraxin PTX3 protein comprising the step of growing the recombinant MS24PTX clone and purifying the human long pentraxin PTX3 protein from the culture medium.
The invention will be now illustrated by means of non limiting examples, referring in particular to the following figures:
Figure 1: pSASSI-hPTX3 map and main features
Figure 2: Growth, viability and productivity in Spinner Flask of (A) MS24PTX clone and (B)
293F/PTX3/2F12 clone.
Figure 3: characterization by SDS-PAGE gradient 4-15% (A) and Size Exclusion
Chromatography (B) of recombinant human PTX3 purified from MS24PTX clone.
Figure 4: FGF2 binding capability of hPTX3 clone 293F/PTX3/2F12 and hPTX3 clone
MS24PTX.
Figure 5: pSCl-hPTX3 map and main features.
EXAMPLES
Example 1: clone 293F/PTX3/2F12
Construction of the Plasmid pSCl-PTX3
1. Construction of pSG/Ub
1.1 Preparation of the Human Ubiquitin C Promoter sequence
The human ubiquitin C promoter is taken from pUB/Bsd plasmid (Invtrogen, Cat. n. V512-20), by amplification with PCR. As part of the cloning strategy, recognition sequences for restriction endonucleases are introduced at both ends. A BsaAI site is built in the upstream amplification primer and an EcoRI site in the downstream primer. The amplified region corresponds to nucleotides 1941 to 3161 in the sequence of pUB/Bsd.
The oligonucleotides are designed as follow:
5'p UbC: length: 26mer (SEQ ID 3) AT ATCACGTG ATC TGG CCT CCG CGC C
3'p UbC: length: 23mer (SEQ ID 4) GGAATTC GGT CCG GTC TAA CAA A
The protocol for amplification is the following: 1 ng/μl of plasmid DNA, 2mM MgC12, 0,2 mM dNTPs, 40OnM of each primer, IX supplied buffer and 0,04 u/ml of Taq DNA polymerase (Sigma Genosys); temperature profile: 3 min 94°C, 30 times (30 sec. 94°C, 30 sec. 46°C, 2 min 72°C), 5 min 72°C, cooling at 4°C until further use.
The amplification product (1238 bp) is purified by silica membrane spin column ( NucleoSpin, Machery-Nagel GmbH & Co.), ligated in pGEM-T-Easy vector (Promega Cat. n. A1360) and transformed into E.coli host strain HB2151 (Pharmacia Biotech). Transformants are selected by growth on LB medium supplemented with 50 mg/1 ampicillin
Plasmids DNA, isolated from ampicillin resistant colonies, are checked by restriction analysis with Stul plus Sad enzymes (expected ~ 3650 and 600 bp fragments)
Plasmids showing the correct restriction pattern are further checked by sequence analysis of the entire insert and subsequently digested with EcoRI (Sigma-Genosys) and BsaAI (New England Biolabs) restriction enzymes.
Human Ubiquitin C promoter is purified via agarose gel separation and elution on silica membrane spin column.
1.2 Preparation of the vector fragment pSG5
Plasmid pSG5 (4076 bp, Stratagene) was cut with the restriction enzymes EcoRI (Sigma- Genosys) and BsaAI (New England Biolabs); the resulting fragments are 1432 and 2644 bp long. The 2644 bp fragment, containing the backbone of pSG5, was prepared and purified via agarose gel electrophoresis plus silica membrane spin column.
1.3 Preparation of pSG/Ub
DNA fragments prepared in steps 1.1 and 1.2 were ligated using T4 DNA ligase (Promega) and transformed in HB2151 E. coli cells. Transformants were selected by growth on LB medium supplemented with 50 mg/1 ampicillin.
Plasmid DNA, isolated from ampicillin resistant colonies, was checked by restriction analysis with EcoRI plus SacII enzymes (expected: 2670 and 1192 bp fragments). A plasmid DNA, with the expected restriction pattern, was designed as pSG/Ub.
2. Construction of pSCl
2.1 Preparation of the Neomycin Resistance Cassette (NeoR)
The Neomycin Resistance Cassette (NeoR) was taken from pcDNA3 plasmid (5446 bp, Invitrogen), amplifying it by PCR. As part of the cloning strategy, recognition sequences for restriction endonuclease AflIII were introduced at both ends. The amplified region corresponds to nucleotides 1788 to 3252 in the sequence of pcDNA3 and includes the SV40 promoter and origin of replication, the neomycin resistance ORF, and the SV40 poliA signal.
The oligonucleotides are designed as follows: 5'NeoR (SEQ ID 5) ATATACATG TCC CCA GGC AGG CAG AA
3'NeoR (SEQ ID 6) ATATACAT GTAT ACA GAC ATG ATA AG
Protocol for amplification was the following: 1 ng/μl of plasmid DNA, 2mM MgC12, 0,2 mM dNTPs, 40OnM of each primer, IX supplied buffer and 0,04 u/μl of Taq DNA polymerase (Sigma Genosys); temperature profile: 3 min 94°C, 30 times (30 sec. 94°C, 30 sec. 46°C, 2 min
72°C), 5 min 72°C, cooling at 4°C until further use.
The amplification product (1484 bp) was purified by silica membrane spin column, ligated in pGEM-T-Easy vector (Promega Cat. n. A1360) and transformed into E.coli host strain HB2151.
Trans formants are selected by growth on LB medium, supplemented with 50 mg/1 ampicillin Plasmids DNA, isolated from ampicillin resistant colonies, are checked by restriction analysis with Smal plus Sad enzymes (expected ~ 1200 and 3300 bp fragments).
Plasmids showing the correct restriction pattern were further checked by sequence analysis of the entire insert and subsequently digested with AfIIII (New England Biolabs) restriction enzymes.
NeoR cassette (1471 bp) was purified via agarose gel separation and elution on silica membrane spin column.
2.2 Preparation of the vector fragment pSG/Ub
Plasmid pSG/Ub, prepared in step 1.3, was linearized by AfIIII digestion and purified on silica membrane spin column.
2.3 Preparation of pSCl
DNA fragments prepared as in steps 2.1 and 2.2 were ligated using T4 DNA ligase (Promega) and transformed in JMl 09 E. coli strain (New England Biolabs). Transformants were selected by growth on LB medium, supplemented with 50 mg/1 ampicillin.
Antibiotic resistant colonies were preliminarliy analyzed by PCR amplification with 5 'NeoR and 3 'NeoR oligonucleotides, as previously described, and subsequently, purified plasmids were checked by restriction analysis. For this purpose, Smal (position 602, inside NeoR sequence) and SacII (position 4142, inside UbC sequence) enzymes were used. A plasmid DNA, with the expected restriction pattern (3540 and 1793 bp fragments), was designed as pSCl.
3. Construction of pSCl-PTX3
3.1 Preparation of the hPTX3 coding sequence
The hPTX3 (GeneBank Accession Number BD 131701) sequence was taken from pSG5-PTX3 (WO 99/32516 "Pharmaceutical compositions containing the long pentraxin PTX3 ) by BamHI (Roche Applied Science) digestion. Human PTX3 fragment (1463 bp) was purified by agarose gel electrophoresis and silica membrane spin column. 3.2 Preparation of the vector fragment pSCl
The pSCl vector was linearized by BamHI digestion and purified on silica membrane spin column.
3.3 Construction and verification on pSCl-PTX3
DNA fragments prepared in steps 3.2 and 3.3 were ligated using T4 DNA ligase (Roche Applied Science) and transformed in JM 109 E. coli strain. Transformants were selected by growth on LB medium, supplemented with 50 mg/1 ampicillin and preliminarily screened by PCR with two oligonucleotides complementary to PTX3 sequence.
The oligonucleotides sequences are:
5 'PTX (SEQ ID 7) GTGAGAACTCGGATGATT ATGAT
3'PTX (SEQ ID 8) TGAAAC ATACTGAGCTCCTCCAT
In a final volume of 10 μl, reagents for amplification were: 1 μl of boiled colony (1 colony in 50ml of water), 2mM MgC12, 0,2 mM dNTPs, 32OnM of each primer, 0,06% Formamide, IX supplied buffer and 0,08 u/μl of Taq DNA polymerase (Sigma Genosys); temperature profile: 3 min 96°C, 30 times (30 sec. 94°C, 30 sec. 58°C, 2 min 72°C), 5 min 72°C, cooling at 4°C until further use.
Plasmid purified from colonies positive to PCR screening, were digested with Sail restriction enzyme (Roche Applied Science) to check the orientation of hPTX3 insert. A plasmid with the expected restriction pattern (6619 and 177 bp) was sequenced in the regions coding for UbC promoter, NeoR cassette and hPTX3 and identified as pSCl-PTX3.
The new plasmid (pSCl-PTX3) was then constructed with PTX3 cDNA sequence located under ubiquitin promoter control and neomycin resistance gene under SV40 promoter control; all other features and plasmid map are represented in figure 1.
The complete sequence of pSCl-PTX3 is as follows (SEQ ID 2). The pSCl-hPTX3 sequence is represented starting from the first EcoRI site (figure 5). The sequence deriving from pSG5 containing PTX3 cDNA is underlined. The starting codon (ATG) and termination codon are in bold.
pSCl-PTX3 (SEQ ID 2)
TTTTTTGTTAGACCGGACCG A human cell line (HEK293F) has been chosen for its ability to grow in suspension and in a serum and protein free medium (Florian M Wurm "Production of recombinant protein therapeutics in cultivated mammalian cells" Nature Biotechnology 22(11): 1393-1398, 2004, Yan SC et al. "Characterization and novel purification of recombinant human protein C from three mammalian cell lines" Biotechnology (N.Y.) 1990 JuI 8 (7): 655-61. "Use of cell lines for the production of influenza virus vaccines: an appraisal of technical, manufacturing, and regulatory considerations" Initiative for Vaccine Research, World Health Organization, Geneva, Switzerland (10 Aprile 2007). To transfect HEK293F, pSCl-PTX3 plasmid was used either in a linear (Pvul digested) or in a circular form. The best transfection yield was obtained with linearized plasmid; clones selection was done on a productivity base and growth capability. After several rounds of subcloning the 2Fl 2 clone was selected.
The human clone 2Fl 2, expressing hPTX3, has been deposited at ECACC (European Collection of Cell Cultures, Health Protection Agency, Porton Down, Wiltshire SP4 OJG, UK) on January 10, 2008, pursuant to Budapest Treaty condition under deposit number 0801 1001. The experimental details are described below.
3.4 Recombinant 293F-cells generated from pSC 1 -PTX3
Transfection and subcloning
106 cells/ml 293F (Invitrogen cat n° R790-07) were seeded in a 125 ml spinner flask in a final Freestyle medium volume of 28 ml the day of transfection. The pSCl/PTX3 plasmid was then allowed to adsorb to the 293fectin reagent (GIBCO/Invitrogen) according to the manufacturer's protocol.
In brief, in two separate tube, 30 μg of pSCl-PTX3 circular or Pvul linearized were diluted in 1 ml of Optimem (GIBCO/Invitrogen, Carlsbad, CA, USA) and 40 μl of 293fectin (Invitrogen) diluted to 1 ml with Optimem. Both solution were incubated for 5 minutes at room temperature then mixed (final volume 2 ml) and incubated for 30 minutes in the same conditions. DNA/lipid cocktail was added to cells and incubated at 37°C, 5% CO2 with agitation (120 rpm). After cultivation for 36 hours, the medium was changed into selection medium (200 ml Freestyle medium+ 500 μg/ml of G418) and the transfected cells were plated in ten 96wells plates, 200μl/well. After 15 days highest producers cell-pools were determined by ELISA and amplified in 24wells, βwells and T25flask.
Recombinant cell-pools obtained were subcloned with 1 cells per well in 96wells plates, in 50% fresh medium and 50% conditioned medium.
Example 2: clone MS24PTX
Construction of the plasmid pSASSI-hPTX3
1. Construction of pCEPlightΔ
pCEP4 plasmid (Invitrogen cat. n. V044-50), in which was previously cloned an antibody light chain, loosing a portion of the Multiple Cloning Site and the BamHI restriction site, was cut with the restriction enzymes EcoRV and CIaI (Roche Applied Science); the digestion allowed to obtain a plasmid without the Epstein-Barr- Virus replication origin (oriP) and the nuclear antigen (encoded by the EBNA-I gene) that permit extrachromosomal replication. The resulting fragments were 6910 and 4281 bp long. The 6910 bp fragment, containing the backbone of pCEP, was purified via agarose gel electrophoresis plus silica membrane spin column. Since CIaI generates sticky end, the fragment was filled in, using T4 DNA polymerase (Roche Applied Science) with the follow protocol: 150 ng of Clal/EcoRV purified fragment (38 μl), 5 μl of 10x T4 DNA polymerase buffer, 4 μl of dNTP mix 2.5mM, 3 μl of T4 DNA polymerase (lU/μl). After 15 minutes at 37°C, the reaction was stopped at 700C for 5 minutes then on ice. The fragment was purified on a silica membrane spin column and ligated on itself over night at room temperature, by using T4 DNA ligase (Promega). TOPlO competent cells (Invitrogen) were transformed with the ligation mixture and transformants selected by growth on LB plates supplemented with 100 mg/L ampicillin.
Plasmid DNA, isolated from ampicillin resistant colonies, was designed as pCEPlightΔ.
2. Preparation of vector fragment containing Hygromycin resistance and CMV promoter.
The Hygromycin Resistance Cassette together with the cytomegalovirus (CMV) immediate early enhancer/promoter was taken from pCEPlightΔ amplifying it by PCR. As a part of the cloning strategy, recognition sequence for restriction endonuclease BamHI was introduced in the oligonucleotide annealing to the 3' end of CMV promoter.
The amplified region about 5500 bp, included CMV promoter, Hygromycin gene under the control of TK promoter together with TK polyA signal.
The oligonucleotide are designed as follows:
oligo CMV (SEQ ID 9) 5 'GAGAACTGTAACGTTGGATCCAGCTGG S '
oligo H (SEQ ID 10) 5 'GTGTACAAAGGATCCAGACATGATAAG 3'
Protocol for amplification was the following: 2 ng of pCEPlightΔ, 20OnM of each primer, 0,2 mM dNTPs, IX supplied buffer, 1.5 μl DMSO, 0.5 μl Taq DNA polymerase (Phusion), final volume 50 μl; temperature profile: 1 min 98°C, 35 times (10 sec. 98°C, 30 sec. 55°C, 3 min. 72°C), 10 min. 72°C, cooling at 4°C until further use.
The amplification product (-5500 bp) was purified via agarose gel electrophoresis plus silica membrane spin column. Purified fragment was ligated to itself and use to transform TOPlO competent cells (Invitrogen). Plasmid DNA, isolated from ampicillin resistant colonies, was checked by restriction and sequence analysis, and was designed as pCEPΔBam.
3. Preparation of hPTX3 gene
The hPTX3 (GeneBank Accession Number BD 131701) sequence was taken from pSCl-PTX3 as indicated above by BamHI (Roche Applied Science) digestion. Human PTX3 fragment (1463 bp) was purified by agarose gel electrophoresis and silica membrane spin column.
4. Preparation of pCEPΔBam-hPTX3
The pCEPΔBam vector was linearized by BamHI digestion and purified on silica membrane spin column. pCEPΔBam linearized and DNA fragment corresponding to hPTX3 gene prepared in step 3 were ligated using T4 DNA ligase (Roche Applied Science) and used to transform TOPlO E. coli strain. Transformants were selected by growth on LB medium, supplemented with 100 mg/L ampicillin and preliminarily screened restriction analisys to evaluate PTX3 fragment orientation.
5. Preparation of SV40 polyadenilation signal
The SV40 polyA signal was taken from pCEPΔlight plasmid amplifying it by PCR. As part of the cloning strategy, recognition sequences for restriction endonucleoases HindIII and Xhol were introduced at fragment ends respectively.
The oligonucleotides were designed as follows:
PCEPSVH (SEQ ID 11) 5 'AAGCTT AGAC ATGAT AAGAT AC ATTG 3'
PCEPSVX (SEQ ID 12) 5'CTCGAGAGTCGACCGGTCATGGCTGC 3' Protocol for amplification was the following: 1 ng of pCEPlightΔ, 20OnM of each primer, 0,2 mM dNTPs, IX supplied buffer, 2 μl MgC12 5OmM, 0.5 μl Taq DNA polymerase (Invitrogen), final volume 50 μl; temperature profile: 1 min 94°C, 30 times (30 sec. 94°C, 1 min. 55°C, 1 min. 72°C), 15 min. 72°C, cooling at 4°C until further use.
The amplification product (-420 bp) was purified via agarose gel electrophoresis plus silica membrane spin column.
6. Preparation of pSASSI-hPTX3
Purified fragment corresponding to SV40 polyA signal and pCEPΔBam-hPTX3 were digested with Hindlll/Xhol restriction enzymes and ligated using T4 DNA ligase (Promega). Ligation mixture was used to transform TOPlO competent cells (Invitrogen) and transformants were selected by growth on LB plates containing 100 mg/L of ampicillin.
Plasmid DNA isolated from ampicillin resistant colonies, was checked by restriction and sequence analysis and the plasmid was designated pSASSI-hPTX3.
The complete sequence of pSASSI-HPTX3 is as follow (SEQ ID 1). The pSASSI-hPTX3 sequence is represented starting from the BamHI site (figure 1). The sequence of hPTX3 is in small letters. The starting codon (atg) and the termination codon (taa) are in bold.
pSASSI-HPTX3 (SEQ ID 1).
GGATCCCCCG GGCTGCAGGA ATTCCGGCTC AAACTCAGCT CACTTGAGAG TCTCCTCCCG 60 CCAGCTGTGG AAAGAACTTT GCGTCTCTCC AGCAATGCAT CTCCTTGCGA TTCTGTTTTG 120 TGCTCTCTGG TCTGCAGTGT TGGCCGAGAA CTCGGATGAT TATGATCTCA TGTATGTGAA 180 TTTGGACAAC GAAATAGACA ATGGACTCCA TCCCACTGAG GACCCCACGC CGTGCGACTG 240 CGGTCAGGAG CACTCGGAAT GGGACAAGCT CTTCATCATG CTGGAGAACT CGCAGATGAG 300 AGAGCGCATG CTGCTGCAAG CCACGGACGA CGTCCTGCGG GGCGAGCTGC AGAGGCTGCG 360 GGAGGAGCTG GGCCGGCTCG CGGAAAGCCT GGCGAGGCCG TGCGCGCCGG GGGCTCCCGC 420 AGAGGCCAGG CTGACCAGTG CTCTGGACGA GCTGCTGCAG GCGACCCGCG ACGCGGGCCG 480 CAGGCTGGCG CGTATGGAGG GCGCGGAGGC GCAGCGCCCA GAGGAGGCGG GGCGCGCCCT 540 GGCCGCGGTG CTAGAGGAGC TGCGGCAGAC GCGAGCCGAC CTGCACGCGG TGCAGGGCTG 600 GGCTGCCCGG AGCTGGCTGC CGGCAGGTTG TGAAACAGCT ATTTTATTCC CAATGCGTTC 660 CAAGAAGATT TTTGGAAGCG TGCATCCAGT GAGACCAATG AGGCTTGAGT CTTTTAGTGC 720 CTGCATTTGG GTCAAAGCCA CAGATGTATT AAACAAAACC ATCCTGTTTT CCTATGGCAC 780 AAAGAGGAAT CCATATGAAA TCCAGCTGTA TCTCAGCTAC CAATCCATAG TGTTTGTGGT 840 GGGTGGAGAG GAGAACAAAC TGGTTGCTGA AGCCATGGTT TCCCTGGGAA GGTGGACCCA 900 CCTGTGCGGC ACCTGGAATT CAGAGGAAGG GCTCACATCC TTGTGGGTAA ATGGTGAACT 960 GGCGGCTACC ACTGTTGAGA TGGCCACAGG TCACATTGTT CCTGAGGGAG GAATCCTGCA 1020 GATTGGCCAA GAAAAGAATG GCTGCTGTGT GGGTGGTGGC TTTGATGAAA CATTAGCCTT 1080 CTCTGGGAGA CTCACAGGCT TCAATATCTG GGATAGTGTT CTTAGCAATG AAGAGATAAG 1140 AGAGACCGGA GGAGCAGAGT CTTGTCACAT CCGGGGGAAT ATTGTTGGGT GGGGAGTCAC 1200 AGAGATCCAG CCACATGGAG GAGCTCAGTA TGTTTCATAA ATGTTGTGAA ACTCCACTTG 1260
AAGCCAAAGA AAGAAACTCA CACTTAAAAC ACATGCCAGT TGGGAAGGTC TGAAAACTCA 1320
GTGCATAATA GGAACACTTG AGACTAATGA AAGAGAGAGT TGAGACCAAT CTTTATTTGT 1380
ACTGGCCAAA TACTGAATAA ACAGTTGAAG GAAAGACATT GGAAAAAGCT TAGACATGAT 1440 AAGATACATT GATGAGTTTG GACAAACCAC AACTAGAATG CAGTGAAAAA AATGCTTTAT 1500
TTGTGAAATT TGTGATGCTA TTGCTTTATT TGTAACCATT ATAAGCTGCA ATAAACAAGT 1560
TAACAACAAC AATTGCATTC ATTTTATGTT TCAGGTTCAG GGGGAGGTGT GGGAGGTTTT 1620
TTAAAGCAAG TAAAACCTCT ACAAATGTGG TATGGCTGAT TATGATCCGG CTGCCTCGCG 1680
CGTTTCGGTG ATGACGGTGA AAACCTCTGA CACATGCAGC TCCCGGAGAC GGTCACAGCT 1740 TGTCTGTAAG CGGATGCCGG GAGCAGACAA GCCCGTCAGG GCGCGTCAGC GGGTGTTGGC 1800
GGGTGTCGGG GCGCAGCCAT GACCGGTCGA CTCTCGAGGG GGGGCCCGGG GATCCAACGT 1860
TACAGTTCTC CAGTGCATGT AATCCCTTCA GTTGGTTGGT ACAACTTGCC AACTGGGCCC 1920
TGTTCCACAT GTGACACGGG GGGGGACCAA ACACAAAGGG GTTCTCTGAC TGTAGTTGAC 1980
ATCCTTATAA ATGGATGTGC ACATTTGCCA ACACTGAGTG GCTTTCATCC TGGAGCAGAC 2040 TTTGCAGTCT GTGGACTGCA ACACAACATT GCCTTTATGT GTAACTCTTG GCTGAAGCTC 2100
TTACACCAAT GCTGGGGGAC ATGTACCTCC CAGGGGCCCA GGAAGACTAC GGGAGGCTAC 2160
ACCAACGTCA ATCAGAGGGG CCTGTGTAGC TACCGATAAG CGGACCCTCA AGAGGGCATT 2220
AGCAATAGTG TTTATAAGGC CCCCTTGTTA ACCCTAAACG GGTAGCATAT GCTTCCCGGG 2280
TAGTAGTATA TACTATCCAG ACTAACCCTA ATTCAATAGC ATATGTTACC CAACGGGAAG 2340 CATATGCTAT CGAATTAGGG TTAGTAAAAG GGTCCTAAGG AACAGCGATC GATGATAAGC 2400
TGTCAAACAT GAGAATTCTT GAAGACGAAA GGGCCTCGTG ATACGCCTAT TTTTATAGGT 2460
TAATGTCATG ATAATAATGG TTTCTTAGAC GTCAGGTGGC ACTTTTCGGG GAAATGTGCG 2520
CGGAACCCCT ATTTGTTTAT TTTTCTAAAT ACATTCAAAT ATGTATCCGC TCATGAGACA 2580
ATAACCCTGA TAAATGCTTC AATAATATTG AAAAAGGAAG AGTATGAGTA TTCAACATTT 2640 CCGTGTCGCC CTTATTCCCT TTTTTGCGGC ATTTTGCCTT CCTGTTTTTG CTCACCCAGA 2700
AACGCTGGTG AAAGTAAAAG ATGCTGAAGA TCAGTTGGGT GCACGAGTGG GTTACATCGA 2760
ACTGGATCTC AACAGCGGTA AGATCCTTGA GAGTTTTCGC CCCGAAGAAC GTTTTCCAAT 2820
GATGAGCACT TTTAAAGTTC TGCTATGTGG CGCGGTATTA TCCCGTGTTG ACGCCGGGCA 2880
AGAGCAACTC GGTCGCCGCA TACACTATTC TCAGAATGAC TTGGTTGAGT ACTCACCAGT 2940 CACAGAAAAG CATCTTACGG ATGGCATGAC AGTAAGAGAA TTATGCAGTG CTGCCATAAC 3000
CATGAGTGAT AACACTGCGG CCAACTTACT TCTGACAACG ATCGGAGGAC CGAAGGAGCT 3060
AACCGCTTTT TTGCACAACA TGGGGGATCA TGTAACTCGC CTTGATCGTT GGGAACCGGA 3120
GCTGAATGAA GCCATACCAA ACGACGAGCG TGACACCACG ATGCCTGCAG CAATGGCAAC 3180
AACGTTGCGC AAACTATTAA CTGGCGAACT ACTTACTCTA GCTTCCCGGC AACAATTAAT 3240 AGACTGGATG GAGGCGGATA AAGTTGCAGG ACCACTTCTG CGCTCGGCCC TTCCGGCTGG 3300
CTGGTTTATT GCTGATAAAT CTGGAGCCGG TGAGCGTGGG TCTCGCGGTA TCATTGCAGC 3360
ACTGGGGCCA GATGGTAAGC CCTCCCGTAT CGTAGTTATC TACACGACGG GGAGTCAGGC 3420
AACTATGGAT GAACGAAATA GACAGATCGC TGAGATAGGT GCCTCACTGA TTAAGCATTG 3480
GTAACTGTCA GACCAAGTTT ACTCATATAT ACTTTAGATT GATTTAAAAC TTCATTTTTA 3540 ATTTAAAAGG ATCTAGGTGA AGATCCTTTT TGATAATCTC ATGACCAAAA TCCCTTAACG 3600
TGAGTTTTCG TTCCACTGAG CGTCAGACCC CGTAGAAAAG ATCAAAGGAT CTTCTTGAGA 3660 TCCTTTTTTT CTGCGCGTAA TCTGCTGCTT GCAAACAAAA AAACCACCGC TACCAGCGGT 3720
GGTTTGTTTG CCGGATCAAG AGCTACCAAC TCTTTTTCCG AAGGTAACTG GCTTCAGCAG 3780
AGCGCAGATA CCAAATACTG TCCTTCTAGT GTAGCCGTAG TTAGGCCACC ACTTCAAGAA 3840
CTCTGTAGCA CCGCCTACAT ACCTCGCTCT GCTAATCCTG TTACCAGTGG CTGCTGCCAG 3900 TGGCGATAAG TCGTGTCTTA CCGGGTTGGA CTCAAGACGA TAGTTACCGG ATAAGGCGCA 3960
GCGGTCGGGC TGAACGGGGG GTTCGTGCAC ACAGCCCAGC TTGGAGCGAA CGACCTACAC 4020
CGAACTGAGA TACCTACAGC GTGAGCTATG AGAAAGCGCC ACGCTTCCCG AAGGGAGAAA 4080
GGCGGACAGG TATCCGGTAA GCGGCAGGGT CGGAACAGGA GAGCGCACGA GGGAGCTTCC 4140
AGGGGGAAAC GCCTGGTATC TTTATAGTCC TGTCGGGTTT CGCCACCTCT GACTTGAGCG 4200 TCGATTTTTG TGATGCTCGT CAGGGGGGCG GAGCCTATGG AAAAACGCCA GCAACGCGGC 4260
CTTTTTACGG TTCCTGGCCT TTTGCTGCGC CGCGTGCGGC TGCTGGAGAT GGCGGACGCG 4320
ATGGATATGT TCTGCCAAGG GTTGGTTTGC GCATTCACAG TTCTCCGCAA GAATTGATTG 4380
GCTCCAATTC TTGGAGTGGT GAATCCGTTA GCGAGGTGCC GCCGGCTTCC ATTCAGGTCG 4440
AGGTGGCCCG GCTCCATGCA CCGCGACGCA ACGCGGGGAG GCAGACAAGG TATAGGGCGG 4500 CGCCTACAAT CCATGCCAAC CCGTTCCATG TGCTCGCCGA GGCGGCATAA ATCGCCGTGA 4560
CGATCAGCGG TCCAGTGATC GAAGTTAGGC TGGTAAGAGC CGCGAGCGAT CCTTGAAGCT 4620
GTCCCTGATG GTCGTCATCT ACCTGCCTGG ACAGCATGGC CTGCAACGCG GGCATCCCGA 4680
TGCCGCCGGA AGCGAGAAGA ATCATAATGG GGAAGGCCAT CCAGCCTCGC GTCGCGAACG 4740
GCGAACGCCA GCAAGACGTA GCCCAGCGCG TCGGCCGCCA TGCCCTGCTT CATCCCCGTG 4800 GCCCGTTGCT CGCGTTTGCT GGCGGTGTCC CCGGAAGAAA TATATTTGCA TGTCTTTAGT 4860
TCTATGATGA CACAAACCCC GCCCAGCGTC TTGTCATTGG CGAATTCGAA CACGCAGATG 4920
CAGTCGGGGC GGCGCGGTCC CAGGTCCACT TCGCATATTA AGGTGACGCG TGTGGCCTCG 4980
AACACCGAGC GACCCTGCAG CGACCCGCTT AACAGCGTCA ACAGCGTGCC GCAGATCCCG 5040
GGCAATGAGA TATGAAAAAG CCTGAACTCA CCGCGACGTC TGTCGAGAAG TTTCTGATCG 5100 AAAAGTTCGA CAGCGTCTCC GACCTGATGC AGCTCTCGGA GGGCGAAGAA TCTCGTGCTT 5160
TCAGCTTCGA TGTAGGAGGG CGTGGATATG TCCTGCGGGT AAATAGCTGC GCCGATGGTT 5220
TCTACAAAGA TCGTTATGTT TATCGGCACT TTGCATCGGC CGCGCTCCCG ATTCCGGAAG 5280
TGCTTGACAT TGGGGAATTC AGCGAGAGCC TGACCTATTG CATCTCCCGC CGTGCACAGG 5340
GTGTCACGTT GCAAGACCTG CCTGAAACCG AACTGCCCGC TGTTCTGCAG CCGGTCGCGG 5400 AGGCCATGGA TGCGATCGCT GCGGCCGATC TTAGCCAGAC GAGCGGGTTC GGCCCATTCG 5460
GACCGCAAGG AATCGGTCAA TACACTACAT GGCGTGATTT CATATGCGCG ATTGCTGATC 5520
CCCATGTGTA TCACTGGCAA ACTGTGATGG ACGACACCGT CAGTGCGTCC GTCGCGCAGG 5580
CTCTCGATGA GCTGATGCTT TGGGCCGAGG ACTGCCCCGA AGTCCGGCAC CTCGTGCACG 5640
CGGATTTCGG CTCCAACAAT GTCCTGACGG ACAATGGCCG CATAACAGCG GTCATTGACT 5700 GGAGCGAGGC GATGTTCGGG GATTCCCAAT ACGAGGTCGC CAACATCTTC TTCTGGAGGC 5760
CGTGGTTGGC TTGTATGGAG CAGCAGACGC GCTACTTCGA GCGGAGGCAT CCGGAGCTTG 5820
CAGGATCGCC GCGGCTCCGG GCGTATATGC TCCGCATTGG TCTTGACCAA CTCTATCAGA 5880
GCTTGGTTGA CGGCAATTTC GATGATGCAG CTTGGGCGCA GGGTCGATGC GACGCAATCG 5940
TCCGATCCGG AGCCGGGACT GTCGGGCGTA CACAAATCGC CCGCAGAAGC GCGGCCGTCT 6000 GGACCGATGG CTGTGTAGAA GTACTCGCCG ATAGTGGAAA CCGACGCCCC AGCACTCGTC 6060
CGAGGGCAAA GGAATAGGGG AGATGGGGGA GGCTAACTGA AACACGGAAG GAGACAATAC 6120 CGGAAGGAAC CCGCGCTATG ACGGCAATAA AAAGACAGAA TAAAACGCAC GGGTGTTGGG 6180
TCGTTTGTTC ATAAACGCGG GGTTCGGTCC CAGGGCTGGC ACTCTGTCGA TACCCCACCG 6240
AGACCCCATT GGGGCCAATA CGCCCGCGTT TCTTCCTTTT CCCCACCCCA CCCCCCAAGT 6300
TCGGGTGAAG GCCCAGGGCT CGCAGCCAAC GTCGGGGCGG CAGGCCCTGC CATAGCCACT 6360
GGCCCCGTGG GTTAGGGACG GGGTCCCCCA TGGGGAATGG TTTATGGTTC GTGGGGGTTA 6420
TTATTTTGGG CGTTGCGTGG GGTCTGGTCC ACGACTGGAC TGAGCAGACA GACCCATGGT 6480
TTTTGGATGG CCTGGGCATG GACCGCATGT ACTGGCGCGA CACGAACACC GGGCGTCTGT 6540
GGCTGCCAAA CACCCCCGAC CCCCAAAAAC CACCGCGCGG ATTTCTGGCG TGCCAAGCTA 6600
GTCGACCAAT TCTCATGTTT GACAGCTTAT CATCGCAGAT CCGGGCAACG TTGTTGCCAT 6660
TGCTGCAGGC GCAGAACTGG TAGGTATGGA AGATCTATAC ATTGAATCAA TATTGGCAAT 6720
TAGCCATATT AGTCATTGGT TATATAGCAT AAATCAATAT TGGCTATTGG CCATTGCATA 6780
CGTTGTATCT ATATCATAAT ATGTACATTT ATATTGGCTC ATGTCCAATA TGACCGCCAT 6840
GTTGACATTG ATTATTGACT AGTTATTAAT AGTAATCAAT TACGGGGTCA TTAGTTCATA 6900
GCCCATATAT GGAGTTCCGC GTTACATAAC TTACGGTAAA TGGCCCGCCT GGCTGACCGC 6960
CCAACGACCC CCGCCCATTG ACGTCAATAA TGACGTATGT TCCCATAGTA ACGCCAATAG 7020
GGACTTTCCA TTGACGTCAA TGGGTGGAGT ATTTACGGTA AACTGCCCAC TTGGCAGTAC 7080
ATCAAGTGTA TCATATGCCA AGTCCGCCCC CTATTGACGT CAATGACGGT AAATGGCCCG 7140
CCTGGCATTA TGCCCAGTAC ATGACCTTAC GGGACTTTCC TACTTGGCAG TACATCTACG 7200
TATTAGTCAT CGCTATTACC ATGGTGATGC GGTTTTGGCA GTACACCAAT GGGCGTGGAT 7260
AGCGGTTTGA CTCACGGGGA TTTCCAAGTC TCCACCCCAT TGACGTCAAT GGGAGTTTGT 7320
TTTGGCACCA AAATCAACGG GACTTTCCAA AATGTCGTAA TAACCCCGCC CCGTTGACGC 7380
AAATGGGCGG TAGGCGTGTA CGGTGGGAGG TCTATATAAG CAGAGCTCGT TTAGTGAACC 7440
GTCAGATCTC TAGAAGCTGG GTACCAGCT 7469 Example 3
Recombinant MS24PTX clone generated by pSASSI-hPTX3 transfection
1. Transfection and subcloning
106 cells/ml 293F/PTX3/2F12 were seeded in a 125 ml spinner flask in a final Freestyle medium volume of 28 ml the day of transfection. The pSASSI-hPTX3 plasmid was then allowed to adsorb to the 293fectin reagent (GIBCO/Invitrogen) according to the manufacturer's protocol.
In brief, 30 μg of pSASSI-hPTX3 Nrul linearized was diluted in 1 ml of Optimem (GIBCO/Invitrogen, Carlsbad, CA, USA) and 40 μl of 293fectin (Invitrogen) diluted to 1 ml with Optimem. Both solution were incubated for 5 minutes at room temperature then mixed (final volume 2 ml) and incubated for 30 minutes in the same conditions. DNA/lipid cocktail was added to cells and incubated at 37°C, 5% CO2 with agitation (120 rpm). After cultivation for 36 hours, the medium was changed into selection medium (200 ml Freestyle medium+ 200 μg/ml of Hygromycin) and the transfected cells were plated in ten 96wells plates, 200μl/well. After 15 days highest producers cell-pools were determined by ELISA and amplified in 24wells, βwells and T25 flask.
Recombinant cell-pools obtained were subcloned with 1 cells per well in 96wells plates, in 50% fresh medium and 50% conditioned medium.
2. ELISA detection of recombinant hPTX3
Purified PTX3 or PTX3 secreted in the culture supernatant were titrated using a sandwich ELISA. To detect PTX3, 96-well Nunc Maxisorb microtiter plates (Nunc, Roskilde, Denmark) were coated overnight, at 4°C, with 700 ng/ml of the rat monoclonal antibody MNB4 anti-human PTX3 (Alexis™ Biochemicals, Lausen, Switzerland) in 15mM sodium carbonate buffer, pH 9.6. Wells were washed with PBS plus 0.05% Tween-20 (PBS-Tw, washing solution) and blocked with 300μl of PBS-Tw containing 5% dry milk, for 2 hours at room temperature.
Cell supernatants or purified recombinant human PTX3 were added to the wells, diluted in washing solution plus 1% BSA. A standard curve, made with purified recombinant human PTX3 from CHO cells, ranging from 0 to 100 ng/ml, was done for quantification. After 1 hour of incubation at 37°C, bound PTX3 was detected using biotin-conjugated polyclonal rabbit anti- PTX3 antibody, followed by incubation with streptavidin conjugated to horseradish peroxidase (Sigma-Aldrich, USA). Finally 2.2'-azino-bis 3-ethylbenxthiazoline-6-sulfonic acid (Sigma Chemical Co. USA) was added for color development and optical density at 405 nm was assessed using a Microplate Reader Model 3550 EIA (Bio-Rad, Hercules, CA, USA).
Example 4
Comparison of growth, viability and productivity of clones 293F/PTX3/2F12 and MS24PTX Cells deriving from the two clones were seeded at a density of 1.000.000 cells/ml (viability >90%) in a 500 ml of FreeStyle 293 medium in 1 liter Spinner flasks. The growing, the viability and the productivity were monitored for about 1 week until cells start die.
Figure 2 shows the growth, viability and productivity of the MS24PTX (panel A) and 293F/PTX3/2F12 (panel B) clones in the same seeding and growing conditions. As shown in the figure, with the re-transfection of the PTX3 expressing clone 293F/PTX3/2F12 with a new plasmid in which PTX3 is under the control of CMV promoter (MS24PTX clone) we were able to obtain about 4 fold increase in PTX3 productivity.
Example 5
Purification of recombinant human PTX3 from MS24PTX clone Culture supernantant from MS24PTX clone, grown in spinner flask, was loaded onto a Q- SepharoseTM Fast Flow (GE Healthcare, UK) packed column. Retained material was eluted using a nonlinear gradient. The PTX3 -containing fraction was directly applied to a ceramic Hydroxyapatite (BioRad, Hercules, CA, USA) packed column. The retained material was eluted by increasing phosphate concentration in a nonlinear fashion. The PTX3 -containing fraction was concentrated and buffer changed on a ultrafiltration membrane (Pellicon-Biomax 100, Millipore) than characterized by Size Exclusion Chromatography on Biosep SEC S4000 (Phenomenex) and SDS-PAGE (Figure 3). Example 6
Binding of h-PTX3 to FGF2
The binding of purified recombinant hPTX3 to FGF2 was assessed in an ELISA system. A 96- wells plate (Falcon 3912) was coated with 2 μg/ml of FGF2 (Calbiochem) in PBS and incubated overnight at 4°C. Wells were washed with PBS plus 0.1% Triton X-100 (PBS-Tr, washing solution) and blocked with 200 μl of PBS-Tr containing 3% BSA (PBS-B blocking and diluent solution) for 2 hours at room temperature. After washing, binding was performed adding 100 μl of samples, diluted in PBS-B at PTX3 concentrations ranging from 0 to 120 ng/ml, and incubating the plate at 37°C for 1 hr. After wash, plates were incubated with 100 μl/well of 100 ng/ml rabbit anti-PTX3 polyclonal antibody (1 hr at 37°C), washed again and incubated with 100 μl of horseradish peroxidase-labeled goat anti-rabbit IgG (1 :1000 in PBS-B; 1 hr at 37°C). After washing, 100 μl of chromogenic substrate 3,3 ' ,5,5 '-tetramethylbenzidine (TMB) (sigma- Aldrich) were added and after 10-15 min, the reaction was stopped adding 100 μl of HCl IM and absorbance determined using a Microplate Reader Model 3550 EIA (Bio-Rad, Hercules, CA, USA). (Figure 4).
Print Out (Original in Electronic Form)
(This sheet is not part of and does not count as a sheet of the international application)
FOR RECEIVING OFFICE USE ONLY
0-4 This form was received with the
international application:
(yes or no)
0-4-1 Authorized officer Print Out (Original in Electronic Form)
(This sheet is not part of and does not count as a sheet of the international application)
FOR INTERNATIONAL BUREAU USE ONLY
0-5 This form was received by the
international Bureau on: yes
0-5-1 Authorized officer
Peter WIMMER

Claims

1- An eukaryotic expression vector comprising a nucleotide sequence encoding for the human long pentraxin PTX3 protein under the control of an effective promoter and a nucleotide sequence encoding for a selectable marker, having essentially the sequence of SEQ ID 1.
2- Use of the vector according to claim 1 for transforming a host cell.
3- The use of the vector according to claim 2 wherein the host cell is a recombinant human cell already able to express the human long pentraxin PTX3 protein.
4- The use of the vector according to claim 3 wherein the recombinant human cell is the recombinant 293F/PTX3/2F12 clone deposited at ECACC with no. 08011001. 5- The use of the vector according to any of previous claims wherein the vector is linearized.
6- A recombinant cell able to express the human long pentraxin PTX3 protein encoded by the vector according to any of previous claim 1. 7- The recombinant cell according to claim 6 being a recombinant HEK293F cell line.
8- The recombinant cell according to claim 7 being the recombinant MS24PTX clone .
9- Use of the recombinant cell according to any one of claims 6-8 for the production of human long pentraxin PTX3 protein.
10- A process for the production of the human long pentraxin PTX3 protein comprising:
d) transfecting a recombinant human cell already expressing recombinant human long pentraxin PTX3 protein, with a plasmid in which the human long pentraxin gene is under the control of the CMV promoter;
e) selecting and growing transfected recombinant human cell;
f) purifying the human long pentraxin PTX3 protein from the culture medium of the transfected recombinant human cell. 11- The process according to claim 10 wherein the recombinant human cell expressing a recombinant human long pentraxin PTX3 protein is a recombinant HEK293F cell line.
12- The process according to claim 11 wherein the recombinant HEK293F cell line expressing a recombinant human long pentraxin PTX3 is the recombinant 293F/PTX3/2F12 clone deposited at ECACC under number 08011001.
13- The process according to claim 12 wherein the trans fected recombinant human cell is MS24PTX clone.
14- The process of claims 10 to 13 wherein the purification step includes at least one of the following step: anionic-exchange chromatography, hydro xyapatite chromatography or size exclusion chromatography. 15- A process for the production of the recombinant human long pentraxin PTX3 protein comprising:
a) co-transfecting contemporarily or sequentially human cells with a first vector having essentially the sequence of SEQ ID 1 and a second vector having essentially the sequence of SEQ ID 2;
b) selecting and growing the double transfected cells;
b) purifying the human long pentraxin PTX3 protein from the culture medium of double transfected cells.
16- A process for the production the recombinant human long pentraxin PTX3 protein comprising the step of growing the recombinant MS24PTX clone and purifying the human long pentraxin PTX3 protein from the culture medium.
EP10740573.0A 2009-07-29 2010-07-20 Improved human long pentraxin 3 expression system and uses thereof Active EP2459721B1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP10740573.0A EP2459721B1 (en) 2009-07-29 2010-07-20 Improved human long pentraxin 3 expression system and uses thereof
PL10740573T PL2459721T3 (en) 2009-07-29 2010-07-20 Improved human long pentraxin 3 expression system and uses thereof
MEP-2013-126A ME01566B (en) 2009-07-29 2010-07-20 Improved human long pentraxin 3 expression system and uses thereof
SI201030362T SI2459721T1 (en) 2009-07-29 2010-07-20 Improved human long pentraxin 3 expression system and uses thereof
CY20131100942T CY1116486T1 (en) 2009-07-29 2013-10-25 IMPROVED HUMAN LONG PENTRAXIN 3 EXPRESSION SYSTEM AND ITS USES

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09166759 2009-07-29
EP10740573.0A EP2459721B1 (en) 2009-07-29 2010-07-20 Improved human long pentraxin 3 expression system and uses thereof
PCT/EP2010/060469 WO2011012496A1 (en) 2009-07-29 2010-07-20 Improved human long pentraxin 3 expression system and uses thereof

Publications (2)

Publication Number Publication Date
EP2459721A1 true EP2459721A1 (en) 2012-06-06
EP2459721B1 EP2459721B1 (en) 2013-09-18

Family

ID=41120115

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10740573.0A Active EP2459721B1 (en) 2009-07-29 2010-07-20 Improved human long pentraxin 3 expression system and uses thereof

Country Status (23)

Country Link
US (1) US8883446B2 (en)
EP (1) EP2459721B1 (en)
JP (1) JP5859963B2 (en)
KR (1) KR101767695B1 (en)
CN (1) CN102549160B (en)
AU (1) AU2010277786B2 (en)
BR (1) BR112012001980A2 (en)
CA (1) CA2769257C (en)
CY (1) CY1116486T1 (en)
DK (1) DK2459721T3 (en)
EA (1) EA023191B1 (en)
ES (1) ES2432242T3 (en)
HK (1) HK1172649A1 (en)
HR (1) HRP20130947T1 (en)
IL (1) IL217696A (en)
ME (1) ME01566B (en)
MX (1) MX2012001109A (en)
PL (1) PL2459721T3 (en)
PT (1) PT2459721E (en)
RS (1) RS53006B (en)
SG (1) SG177756A1 (en)
SI (1) SI2459721T1 (en)
WO (1) WO2011012496A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10253321B2 (en) 2013-05-01 2019-04-09 Dna2.0, Inc. Methods, compositions and kits for a one-step DNA cloning system
US9206433B2 (en) * 2013-05-01 2015-12-08 Dna Twopointo, Inc. Methods, compositions and kits for a one-step DNA cloning system
TWI528969B (en) * 2013-06-07 2016-04-11 國立成功大學 Use of amino acid sequence for manufcaturing pharmaceutical compositions for inhibiting ptx3 to treat nasopharyngeal carcinoma

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1298487B1 (en) 1997-12-19 2000-01-10 Sigma Tau Ind Farmaceuti PHARMACEUTICAL COMPOSITIONS INCLUDING PENTRAXIN LONG PTX3 FOR THE THERAPY OF INFECTIOUS, INFLAMMATORY OR CANCER TYPE DISEASES,
CA2492008C (en) * 2002-03-29 2012-06-26 Xoma Technology Ltd. Multigenic vectors plasmids and methods for increasing expression of recombinant polypeptides
EP1832295A1 (en) * 2006-03-10 2007-09-12 Tecnogen S.P.A. Use of PTX3 for the treatment of viral diseases
WO2009095403A1 (en) * 2008-01-29 2009-08-06 Tecnogen S.P.A. Expression system and uses thereof for the production of human long pentraxin 3

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2011012496A1 *

Also Published As

Publication number Publication date
US8883446B2 (en) 2014-11-11
WO2011012496A1 (en) 2011-02-03
RS53006B (en) 2014-04-30
CY1116486T1 (en) 2017-03-15
EA023191B1 (en) 2016-05-31
DK2459721T3 (en) 2013-11-04
KR20120047259A (en) 2012-05-11
CA2769257A1 (en) 2011-02-03
CN102549160B (en) 2014-04-02
ME01566B (en) 2014-09-20
BR112012001980A2 (en) 2015-09-01
US20120301873A1 (en) 2012-11-29
SI2459721T1 (en) 2013-11-29
PT2459721E (en) 2013-10-31
IL217696A (en) 2017-06-29
EA201200198A1 (en) 2012-06-29
KR101767695B1 (en) 2017-08-11
JP2013504304A (en) 2013-02-07
EP2459721B1 (en) 2013-09-18
CA2769257C (en) 2017-12-05
AU2010277786A1 (en) 2012-03-01
ES2432242T3 (en) 2013-12-02
SG177756A1 (en) 2012-02-28
JP5859963B2 (en) 2016-02-16
HRP20130947T1 (en) 2013-11-08
AU2010277786B2 (en) 2016-04-14
CN102549160A (en) 2012-07-04
MX2012001109A (en) 2012-03-26
HK1172649A1 (en) 2013-04-26
PL2459721T3 (en) 2014-01-31

Similar Documents

Publication Publication Date Title
AU2020201190B2 (en) Compositions useful in treatment of ornithine transcarbamylase (OTC) deficiency
KR101229418B1 (en) Method for manufacturing active recombinant blood coagulation factor ix
CN111269888B (en) Adipostem cell modified by adipsin gene, preparation method and application thereof
CN114107390B (en) rAAV vector for expressing antibody IgG1 and application thereof
CN112877351A (en) Recombinant plasmid for preventing and treating new coronavirus infection, recombinant lactobacillus expression system and application thereof
US8883446B2 (en) Human long pentraxin 3 expression system and uses thereof
CN112522271A (en) sgRNA and application thereof
CN110846297B (en) Multifunctional fusion enzyme, multifunctional fusion enzyme eukaryotic expression vector and construction method thereof
CN104403998A (en) Improved fat stem cell for epidermis damage repair
CN114277190A (en) Specific DNA fragment, primer, kit and detection method for detecting foreign gene residues in hiPSC
CN110184292A (en) A method of yeast cell surface display functionality Infliximab Fab segment is improved using molecular chaperones
NL2022714B1 (en) Optimised RAG1 deficient SCID Gene Therapy
CN109735558B (en) Recombinant CAR19-IL24 gene, lentiviral vector, CAR19-IL24-T cell and application
CN101892257A (en) Construction for expressing porcine epidemic Cre recombinase carrier pCEP4-Cre
CN109872774B (en) YESS-based method for analyzing protein interaction in prokaryote
US20020103144A1 (en) Retroviral gene transfer vectors
CN111909850B (en) Astaxanthin-producing engineering bacteria based on Dunaliella salina metabolic pathway and CBFD and HBFD of Adonis amurensis, construction and application thereof
RU2805173C1 (en) METHOD FOR PRODUCING GENETICALLY MODIFIED LABORATORY ANIMALS WITH NULL ALLELE OF P2rx3 GENE
KR20110135724A (en) Transgenic chicken containing the human sod-3 gene
CN115161294B (en) Newcastle disease vaccine strain, construction method thereof, poultry immune recognition method and application
CN115667536A (en) Gene therapy for Barde-Videl syndrome
CN111909945B (en) Method for improving protein expression efficiency in clostridium
CN113702340A (en) Method for detecting biological activity of granulocyte colony stimulating factor
CN103995121A (en) Preparation method for colloidal-gold test paper based on single-chain antibody
XbaI pcosC1. 6 47302bp

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20120223

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME RS

RIN1 Information on inventor provided before grant (corrected)

Inventor name: RIVIECCIO, VINCENZO

Inventor name: CASSANI, GIOVANNI

Inventor name: SASSANO, MARICA

Inventor name: ESPOSITO, ADELAIDE

17Q First examination report despatched

Effective date: 20121122

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Ref document number: 602010010403

Country of ref document: DE

Free format text: PREVIOUS MAIN CLASS: C12N0015790000

Ipc: C07K0014710000

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 15/67 20060101ALI20130326BHEP

Ipc: C12N 15/85 20060101ALI20130326BHEP

Ipc: C07K 14/71 20060101AFI20130326BHEP

Ipc: C12N 5/16 20060101ALI20130326BHEP

Ipc: C12N 15/79 20060101ALI20130326BHEP

INTG Intention to grant announced

Effective date: 20130430

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME RS

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

Ref country code: CH

Ref legal event code: NV

Representative=s name: RENTSCH PARTNER AG, CH

REG Reference to a national code

Ref country code: HR

Ref legal event code: TUEP

Ref document number: P20130947

Country of ref document: HR

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 632750

Country of ref document: AT

Kind code of ref document: T

Effective date: 20131015

REG Reference to a national code

Ref country code: RO

Ref legal event code: EPE

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20131024

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: HR

Ref legal event code: T1PR

Ref document number: P20130947

Country of ref document: HR

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602010010403

Country of ref document: DE

Effective date: 20131114

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: NL

Ref legal event code: T3

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2432242

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20131202

REG Reference to a national code

Ref country code: EE

Ref legal event code: FG4A

Ref document number: E008534

Country of ref document: EE

Effective date: 20131022

REG Reference to a national code

Ref country code: NO

Ref legal event code: T2

Effective date: 20130918

REG Reference to a national code

Ref country code: SK

Ref legal event code: T3

Ref document number: E 15079

Country of ref document: SK

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20130402243

Country of ref document: GR

Effective date: 20131118

REG Reference to a national code

Ref country code: PL

Ref legal event code: T3

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602010010403

Country of ref document: DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E019874

Country of ref document: HU

26N No opposition filed

Effective date: 20140619

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602010010403

Country of ref document: DE

Effective date: 20140619

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130918

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MC

Payment date: 20160706

Year of fee payment: 7

Ref country code: LT

Payment date: 20160701

Year of fee payment: 7

Ref country code: EE

Payment date: 20160705

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CY

Payment date: 20160706

Year of fee payment: 7

Ref country code: LV

Payment date: 20160705

Year of fee payment: 7

Ref country code: SI

Payment date: 20160705

Year of fee payment: 7

Ref country code: RO

Payment date: 20160706

Year of fee payment: 7

Ref country code: SK

Payment date: 20160704

Year of fee payment: 7

Ref country code: AL

Payment date: 20160718

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20160713

Year of fee payment: 7

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 8

REG Reference to a national code

Ref country code: CH

Ref legal event code: PCAR

Free format text: NEW ADDRESS: BELLERIVESTRASSE 203 POSTFACH, 8034 ZUERICH (CH)

REG Reference to a national code

Ref country code: LT

Ref legal event code: MM4D

Effective date: 20170720

REG Reference to a national code

Ref country code: EE

Ref legal event code: MM4A

Ref document number: E008534

Country of ref document: EE

Effective date: 20170731

REG Reference to a national code

Ref country code: SK

Ref legal event code: MM4A

Ref document number: E 15079

Country of ref document: SK

Effective date: 20170720

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170720

Ref country code: CY

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170720

Ref country code: LT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170720

REG Reference to a national code

Ref country code: SI

Ref legal event code: KO00

Effective date: 20180320

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170731

Ref country code: SI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170721

Ref country code: SK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170720

Ref country code: LV

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170720

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MK

Payment date: 20160707

Year of fee payment: 7

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20130947

Country of ref document: HR

Payment date: 20180704

Year of fee payment: 9

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20180727

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20180726

Year of fee payment: 9

Ref country code: ES

Payment date: 20180801

Year of fee payment: 9

Ref country code: NO

Payment date: 20180730

Year of fee payment: 9

Ref country code: NL

Payment date: 20180726

Year of fee payment: 9

Ref country code: IE

Payment date: 20180726

Year of fee payment: 9

Ref country code: IT

Payment date: 20180719

Year of fee payment: 9

Ref country code: DE

Payment date: 20180727

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IS

Payment date: 20180702

Year of fee payment: 9

Ref country code: BE

Payment date: 20180727

Year of fee payment: 9

Ref country code: CH

Payment date: 20180801

Year of fee payment: 9

Ref country code: AT

Payment date: 20180705

Year of fee payment: 9

Ref country code: HU

Payment date: 20180712

Year of fee payment: 9

Ref country code: HR

Payment date: 20180704

Year of fee payment: 9

Ref country code: GB

Payment date: 20180727

Year of fee payment: 9

Ref country code: DK

Payment date: 20180727

Year of fee payment: 9

Ref country code: SM

Payment date: 20180726

Year of fee payment: 9

Ref country code: BG

Payment date: 20180730

Year of fee payment: 9

Ref country code: PL

Payment date: 20180702

Year of fee payment: 9

Ref country code: FI

Payment date: 20180727

Year of fee payment: 9

Ref country code: CZ

Payment date: 20180710

Year of fee payment: 9

Ref country code: SE

Payment date: 20180727

Year of fee payment: 9

Ref country code: GR

Payment date: 20180730

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PT

Payment date: 20180706

Year of fee payment: 9

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170731

REG Reference to a national code

Ref country code: HR

Ref legal event code: PBON

Ref document number: P20130947

Country of ref document: HR

Effective date: 20190720

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602010010403

Country of ref document: DE

REG Reference to a national code

Ref country code: NO

Ref legal event code: MMEP

Ref country code: DK

Ref legal event code: EBP

Effective date: 20190731

REG Reference to a national code

Ref country code: FI

Ref legal event code: MAE

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 632750

Country of ref document: AT

Kind code of ref document: T

Effective date: 20190720

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20190720

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20190731

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190720

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200120

Ref country code: HU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190721

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200201

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190801

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200206

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190720

Ref country code: FI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190720

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190721

Ref country code: NO

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190731

Ref country code: BG

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200131

REG Reference to a national code

Ref country code: NL

Ref legal event code: MM

Effective date: 20190801

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190731

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190731

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190731

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190720

Ref country code: SM

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200203

Ref country code: HR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190720

Ref country code: CZ

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190720

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190731

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190731

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190720

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190720

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20201201

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190721

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190801

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170720

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190720

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170720